Skip to main content

Table 1 Baseline characteristics of patients included in the study

From: Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER

Variable Median (IQR) (Years) No. (%)
Total number of patients   469
Sex, female   216 (46.1)
Agea 32.8 [22.8–43.6]  
Age at diagnosis 10.3 [4.4–14.3]  
Age at the beginning of biological treatment, median [IQR]** 22.1 [13.9–32.5]  
Years of disease progression 22.5 [12.3–33.9]  
Time in treatment with biologic 9.7 [6.8–12.6]  
JIA categories:
 - Oligoarticular, polyarticular, and systemic 331(70.5)
 - Enthesitis-related arthritis 117 (25)
 - Psoriatic arthritis 21 (4.5)
Positive RF 32 (6.8)
ANA-positive 111 (23.7)
HLA-B27-positive:
 - Positive 103 (22)
 - Negative 98 (20.9)
 - Not done 268 (57.1)
Uveitis:
 - Without uveitis 410 (87.4)
 - Uveitis, ANA-negative 30 (6.4)
 - Uveitis, ANA-positive 29 (6.2)
  1. Abbreviations: ANA Antinuclear antibodies, HLA Human leukocyte antigen, JIA Juvenile idiopathic arthritis, RF Rheumatoid factor
  2. aAge at the end of BIOBADASER phase II (December 2015)